Format

Send to

Choose Destination
J Mol Diagn. 2016 Jan;18(1):131-43. doi: 10.1016/j.jmoldx.2015.08.004. Epub 2015 Nov 20.

High-Resolution Genomic Profiling of Disseminated Tumor Cells in Prostate Cancer.

Author information

1
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
2
Department of Urology, University of Washington, Seattle, Washington.
3
Department of Urology, Puget Sound VA Health Care System, Seattle, Washington.
4
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; Department of Urology, University of Washington, Seattle, Washington.
5
Department of Urology, University of Washington, Seattle, Washington; Department of Urology, Puget Sound VA Health Care System, Seattle, Washington.
6
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; Department of Urology, University of Washington, Seattle, Washington. Electronic address: mfang@fhcrc.org.

Abstract

Circulating tumor cells and disseminated tumor cells (DTCs) are of great interest because they provide a minimally invasive window for assessing aspects of cancer biology, including tumor heterogeneity, a means to discover biomarkers of disease behavior, and a way to identify and prioritize therapeutic targets in the emerging era of precision oncology. However, the rarity of circulating tumor cells and DTCs poses a substantial challenge to the consistent success in analyzing their molecular features, including genomic aberrations. Herein, we describe optimized and robust methods to reproducibly detect genomic copy number alterations in samples of 2 to 40 cells after whole-genome amplification with the use of a high-resolution single-nuclear polymorphism-array platform and refined computational algorithms. We have determined the limit of detection for heterogeneity within a sample as 50% and also demonstrated success in analyzing single cells. We validated the genes in genomic regions that are frequently amplified or deleted by real-time quantitative PCR and nCounter copy number quantification. We further applied these methods to DTCs isolated from individuals with advanced prostate cancer to confirm their highly aberrant nature. We compared copy number alterations of DTCs with matched metastatic tumors isolated from the same individual to gain biological insight. These developments provide high-resolution genomic profiling of single and rare cell populations and should be applicable to a wide-range of sample sources.

PMID:
26607774
PMCID:
PMC4715223
DOI:
10.1016/j.jmoldx.2015.08.004
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center